ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2025 and some content may be unavailable. To unlock all content for 2025, please visit the archives.

Abstract: FR-PO0534

Continuous Ambulatory Peritoneal Dialysis for Refractory Ascites in Chronic Liver Disease and ESRD: Feasibility, Safety, and Clinical Outcomes

Session Information

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis

Authors

  • Gupta, Anurag, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Bhargava, Vinant, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Saha, Rajdeb, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Tiwari, Vaibhav, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Malik, Manish, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Gupta, Ashwani, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Bhalla, Anil, Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
  • Rana, Devinder S., Sir Ganga Ram Hospital Department of Nephrology, New Delhi, DL, India
Background

Refractory ascites in patients with chronic liver disease (CLD) and end-stage renal disease (ESRD) presents high morbidity. Hemodialysis (HD) often complicates fluid removal due to intradialytic hypotension. Continuous Ambulatory Peritoneal Dialysis (CAPD) is a potential alternative, but data on its suitability in this cohort are limited. This study evaluated serum albumin changes, peritonitis rates, and overall CAPD suitability in CLD patients with refractory ascites transitioning from HD.

Methods

This retrospective cohort study (Jan 2018-Mar 2023) included adult HD patients (≥6 months) with CLD and refractory ascites (>5 paracenteses/last 3 months despite optimal management). Patients received high-protein diet counseling and regular multidisciplinary follow-up.

Results

Thirty-four patients were analyzed. Pre-CAPD, mean ascites drainage was every 3.4 weeks. At 12 months on CAPD, serum albumin non-significantly increased from 2.98 ± 0.4 g/dL to 3.1 ± 0.28 g/dL (p=0.21). (Figure 1) Child-Pugh and MELD scores remained stable. Bacterial peritonitis incidence at 12 months was higher (p=0.04) compared to baseline spontaneous bacterial peritonitis on HD. Manageable PD-related complications included one omental wrap, three pericatheter leaks, and one umbilical hernia. At 12-month follow-up, 94.1% (32 patients) survived; one death was from myocardial infarction, another from severe hepatic encephalopathy/aspiration pneumonia.

Conclusion

CAPD was well-tolerated in CLD patients with refractory ascites, without worsening hypoalbuminemia. Continuous multidisciplinary monitoring for malnutrition is crucial. While peritonitis risk was elevated compared to SBP on HD, it was comparable to typical PD rates and did not increase hospital admissions, suggesting CAPD is a viable management strategy.

Funding

  • Clinical Revenue Support

Digital Object Identifier (DOI)